Analysis of the short‐term outcomes of biportal robot‐assisted lobectomy

Background The present study aimed to assess the short‐term consequences of biportal robot‐assisted lobectomy, validating its safety and effectiveness. Methods A retrospective analysis evaluated the clinical data and short‐term results of 18 patients in the single medical group of the centre who underwent biportal robot‐assisted lobectomy plus lymph node dissection from November 2020 to March 2021. Results Lobectomy and lymph node dissection could be successfully accomplished in all 18 patients with the assistance of a biportal robot; there was no conversion to thoracotomy during the operation. There were 10 males and 8 females with their ages ranging from 37 to 73 (58.83 ± 9.07) years. The total operation time was 74–146 (105.06 ± 18.22) min. Punching time was 2–9 (5.11 ± 1.74) min. Docking time was 8–16 (11.94 ± 2.41) min. Console time was 50–104 (78.06 ± 17.40) min. Chest closing time was 8–17 (10.28 ± 2.74) min. Blood loss was 60–132 (94.11 ± 41.41) ml. The number of lymph nodes dissected was 16–30 (21.78 ± 4.13). Chest tube duration was 2–10 (4.06 ± 1.98) days. Drainage on the first day following surgery was 100–500 (337.22 ± 117.01) ml. Total drainage was 370–1100 (692.78 ± 161.01) ml. Duration of hospital stay was 4–12 (5.89 ± 1.94) days. The median 24 and 72 h visual analogue score scores were 4 (3–7) and 3 (2–5). Total cost (¥) was 51 000–85 000 (68 000 ± 10 000), respectively. There was one case of atrial fibrillation and one case of pulmonary infection. The complication rate was 11.11%. No serious complications were recorded after surgery, and no deaths occurred within 30 days post‐surgery. The final pathological diagnosis revealed 10 cases of squamous cell carcinoma, 7 cases of adenocarcinoma and 1 case of benign disease. Conclusion The biportal robot‐assisted lobectomy was found to be safe and effective in the treatment of lung cancer.